ClinicalTrials.gg
CompletedNCT02376075Updated Mar 3, 2015

Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria

A Phase 3 interventional study of Linagliptin and Placebo in Arterial Hypertension and Albuminuria, sponsored by ikfe-CRO GmbH. Completed at 1 site in Germany. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-03-03.

Sponsored by ikfe-CRO GmbH · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 282 studies in Hypertension with a site in Germany — 30 open to participants now, 46 under way, 11 of them phase 3. Hypertension · Germany.

Enrollment
223rd of 250
43 · median 200
Started
2013
with 14 others
Phase 3
122 of 282
6 open now
Registered
186th of 282
by date

Among the 282 studies in Hypertension with a site in Germany, this one is the 223rd largest by enrollment of the 250 interventional ones that give a count, is one of 15 that started in 2013, is one of 122 in phase 3, and was the 186th registered.

Hypertension

6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.

Browse Hypertension studies →

Open to participants now

30 of the 282 studies in Hypertension with a site in Germany are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 282 studies in Hypertension with a site in Germany, or all of them as a file.
02

Study summary

A recent study with the DPP-IV inhibitor Linagliptin showed an improvement in the urinary albumin creatinine ratio in patients with diabetic nephropathy. Gutzwiller et. Al. have shown that GLP-1 increases renal Na secretion and inhibits renal H secretion, further indicating some direct renal effects of GLP-1.

Therefore, it seems likely that treatment with the DPP-IV inhibitor Linagliptin evolves several beneficial effects on microvascular and endothelial function beyond glucose control which most probably have an impact on the progression of renal and retinal microvascular disease.

The objective of this trial is to investigate the effect of Linagliptin in comparison to placebo on the UACR in patients with high blood pressure and an increased albumin excretion. Numerous, equivalent endothelial, renal, and retinal parameters serve as objectives of the study. All study parameters will be handled in an exploratory sense for the generation of models to further discuss the role of DPP-IV inhibition on renal and retinal physiology.

Read the detailed description

Renal tissue damage and an increase in the albumin excretion rate is a strong predictor for the development and progression of endothelial dysfunction and the development of microvascular and/or macrovascular complications. Increased blood pressure as well as increased glucose levels were found to impair renal- and retinal function, and a close association in the incidence and progression rate of retinopathy and nephropathy could be observed. Endothelial dysfunction and alterations in microvascular blood flow are early pathogenetic features in the development of renal and retinal tissue damage as found in patients with arterial hypertension and / or diabetes mellitus. A couple of studies have shown that urinary albumin excretion is associated with morphological and functional alterations in retinal microvascular blood flow. In patients with arterial hypertension blood pressure lowering treatment were shown to decrease the albumin excretion rate and to improve endothelial function of the retinal vasculature.

Recently DPP-IV Inhibitors have been introduced in the treatment of type 2 diabetes mellitus. Beside the metabolic effects of this drug class, several pleiotropic effects beyond metabolic control were documented in numerous studies, and are the topic of ongoing clinical research. Treatment with DPP-IV inhibitors was found to improve myocardial and endothelial function, to improve blood lipids, to lower blood pressure and to improve markers of renal function. GLP-1 receptors in vessels, kidney and the heart might account for those glucose independent effects of GLP-1. However, it is also conceivable that DPP-IV inhibition might exert vascular effects independent from GLP-1. In vitro studies demonstrated that DPP-IV is expressed in endothelial cells, and the inhibition of DPP-IV reduced the microvascular tone through direct mediation of the nitric oxide system. Therefore, it seems conceivable that the glucose independent effects of DPP-IV inhibition might be mediated through GLP-1 receptor signaling and /or direct inhibition of the enzyme DPP-IV in vascular, renal, or retinal cells.

A recent study with the DPP-IV inhibitor Linagliptin showed an improvement in the urinary albumin creatinine ratio in patients with diabetic nephropathy. Gutzwiller et. Al. have shown that GLP-1 increases renal Na secretion and inhibits renal H secretion, further indicating some direct renal effects of GLP-1.

Therefore, it seems likely that treatment with the DPP-IV inhibitor Linagliptin evolves several beneficial effects on microvascular and endothelial function beyond glucose control which most probably have an impact on the progression of renal and retinal microvascular disease.

The objective of this trial is to investigate the effect of Linagliptin in comparison to placebo on the UACR in patients with high blood pressure and an increased albumin excretion. Numerous, equivalent endothelial, renal, and retinal parameters serve as objectives of the study. All study parameters will be handled in an exploratory sense for the generation of models to further discuss the role of DPP-IV inhibition on renal and retinal physiology.

03

Conditions studied

  • Arterial Hypertension
  • Albuminuria
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has signed and dated written to participate in the trial
  • Arterial hypertension
  • Stable antihypertensive treatment within the last 3 months
  • Age ≥ 45 - ≤ 80 years
  • Micro- or macroalbuminuria defined as UACR in morning urine > 20 mg/g in female and > 30 mg/g in male and/or arterial hypertension for more than 5 years currently treated with two or more antihypertensive drugs to control blood pressure and a history of cardiovascular disease or stroke.
  • Patient consents that his/her family physician will be informed of trial participation

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes
  • History of type 2 diabetes
  • Uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg)
  • Acute infections
  • Any history of glomerulonephritis
  • Any kidney disease not caused by hypertension as judged by the Investigator
  • (GFR) \< 30 ml/min (estimated by use of the Modification of Diet in Renal Disease (MDRD) formula)
  • Medical history of to the study drugs or to drugs with similar chemical structures
  • History of severe or multiple allergies
  • Treatment with any other drug within 3 months before trial entry
  • Progressive fatal disease
  • History of drug or alcohol abuse in the past 2 years
  • Condition after kidney transplantation
  • Serum potassium > 5.5 mmol/L
  • Pregnancy or breast feeding
  • Sexually active woman of childbearing age not practicing a highly effective method of as defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, sexual abstinence or vasectomised partner.
  • Acute myocardial infarction, open heart surgery or cerebral event (stroke/) within the previous 3 months
  • Any elective surgery during study participation
  • Uncontrolled unstable angina pectoris
  • Intake of Coumarin or coumarin derived compounds such as phenprocoumon (Marcumar) or warfarin (Coumadin, Warfant)
  • Intake of rifampicin or carbamazepine
  • ≥ 6,5%
  • A of > 35 kg/m²
  • CHF stage III - IV
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo, tablets, administered once daily as add on to pre-existing antihypertensive treatment

    Drug: Placebo

  • Active comparator
    Linagliptin

    Linagliptin, tablets containing 5 mg, administered once daily as add on to pre-existing antihypertensive treatment

    Drug: Linagliptin

Interventions

  • Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks

    Also known as: Trajenta

  • DrugPlacebo

    Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks

06

What researchers measure

Primary outcomes

  1. Albumin/Creatinine Ratio (UACR) in 24h urine change between Baseline and Visit 4

    Time frame: up to 14 weeks of study drug intake

Secondary outcomes

  1. 24 hour urinary sodium excretion change between Baseline and Visit 4

    Time frame: after 14 weeks of study drug intake

  2. Fasting cystatin C change between Baseline and V4

    Time frame: up to 14 weeks of study drug intake

  3. Fasting cGMP change between Baseline and Visit 4

    Time frame: after 14 weeks of study drug intake

  4. Fasting serum ADMA change between Baseline and V4

    Time frame: up to 14 weeks of study drug intake

  5. Fasting hsCRP change between Baseline and Visit 4

    Time frame: up to 14 weeks of study drug intake

  6. Fasting TGF-ß1 change between Baseline and Visit 4

    Time frame: after 14 weeks of study drug intake

  7. Retinal endothelial function change between Baseline and Visit 4

    Time frame: up to 14 weeks of study drug intake

  8. Retinal microvascular blood flow change between Baseline and Visit 4

    Time frame: up to 14 weeks of study drug intake

  9. 24h blood pressure measurements change between Baseline and Visit 4

    Time frame: up to 14 weeks of study drug intake

  10. HbA1c change between Baseline and Visit 4

    Time frame: up to 14 weeks of study drug intake

  11. Body weight change during study participation

    Time frame: up to 14 weeks of study drug intake

  12. Adverse events during study participation

    Time frame: up to 14 weeks of study drug intake

07

Study locations

1 site
  • Profil Mainz GmbH & Co. KG
    Mainz, Rhineland-Palatinate 55116, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2015
First posted
Mar 3, 2015
Start
Jan 2013
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Last update
Mar 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02376075
Lead sponsor
ikfe-CRO GmbH
Collaborators
Ikfe GmbH, MLM Medical Labs GmbH
Responsible party
Sponsor
First posted
Mar 3, 2015
Start date
Jan 2013
Primary completion
Sep 2014
Completion
Sep 2014
Last update
Mar 3, 2015

Study contacts

Thomas Forst, MD, PhD
principal investigator · Profil GmbH Mainz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion